7/31/2023 0 Comments Blueprint medicinesWe'd need to see some sustained improvements in the key metrics before we could muster much enthusiasm. However, the loss over the last year isn't as bad as the 4% per annum loss investors have suffered over the last half decade. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Investors in Blueprint Medicines had a tough year, with a total loss of 3.7%, against a market gain of about 6.9%. If you are thinking of buying or selling Blueprint Medicines stock, you should check out this free report showing analyst consensus estimates for future profits. The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).īlueprint Medicines is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. So now is probably an apt time to look closer at the stock, if you think it has potential. You could say that the market has been harsh, given the top line growth. The share price drop of 4% per year over five years would be considered let down. That's better than most loss-making companies. Over five years, Blueprint Medicines grew its revenue at 28% per year. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. See our latest analysis for Blueprint Medicinesīlueprint Medicines isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies. In fact, the share price is down 24%, which falls well short of the return you could get by buying an index fund. But if you look at the last five years the returns have not been good. ![]() It is doubtless a positive to see that the Blueprint Medicines Corporation ( NASDAQ:BPMC) share price has gained some 35% in the last three months.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |